The NeurologyLive® dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
September 5th 2025
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 5, 2025.
September 3rd 2025
FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer Disease
Published: August 29th 2025 | Updated: September 2nd 2025The autoinjector, branded as Leqembi Iqlik, contains a 360 mg/1.8 mL dose administered over 15 seconds. It is expected to enhance Alzheimer treatment accessibility and offer cost savings for patients.
Exploring Orexin Neuron Loss as an Early Driver of Sleep Disturbances in Alzheimer Disease
August 22nd 2025Lea Grinberg, MD, PhD, a neuropathologist at Mayo Clinic Florida, discussed how tau accumulation and orexin neuron loss drive early sleep disturbances in Alzheimer disease and the potential for sleep-based biomarkers.
Preparing for the AI-Driven Future of Neurology: Elisabeth Marsh, MD
August 13th 2025The associate professor of neurology at Johns Hopkins Medicine previewed a 2025 AUPN panel exploring AI’s clinical, research, and educational applications, along with the ethical considerations shaping its responsible adoption. [WATCH TIME: 2 minutes]
Advances in Alzheimer Disease Screening and Antibody Therapy at AAIC 2025: Eric Siemers, MD
August 13th 2025The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]
Targeting Amyloid-ß Oligomers With Investigational Alzheimer Disease Therapy Valiltramiprosate
August 12th 2025Sam Gandy, MD, PhD, director of the Center for Cognitive Health at the Icahn School of Medicine at Mount Sinai, discussed his presentation on detecting toxic amyloid-β oligomers and their role in AD pathology at AAIC 2025.
Importance of Patient Selection and Future Therapies in Alzheimer Treatment
August 10th 2025In the third episode, Salloway emphasizes the need for careful patient selection when prescribing donanemab to minimize serious risks, highlighting the value of the newly approved safer dosing regimen. Supported by Eli Lilly.
Maintaining Efficacy in Safer Donanemab Dosing Regimen
August 9th 2025Dementia expert Stephen Salloway, MD, PhD, overviews the stepwise donanemab regimen approved by the FDA, citing how it not only reduces ARIA rates but preserves the same level of amyloid reduction as the original dosing. Supported by Eli Lilly.
Openwater’s LIFU Technology at MIT: A New Era for Consciousness and Neurological Care
August 7th 2025Daniel Freedman, PhD, of MIT, gave clinical commentary on how Openwater’s Open-LIFU enables new research into conscious perception and potential clinical applications for conditions like pain and depression.
Donanemab Receives CHMP Positive Opinion as Treatment for Early Symptomatic Alzheimer Disease
August 7th 2025Donanemab has received a positive opinion from the European Medicines Agency’s CHMP for the treatment of early symptomatic Alzheimer disease, bringing Eli Lilly’s anti-amyloid therapy one step closer to approval in the European Union.